AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06420089
Drug: Senza5 CART5
RxNorm normalized name: prilocaine
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The Senza5 CART5 drug product consists of a dual population of engineered autologous T cells: CD5 knockout (KO)cells and CD5KO-CART5 cells
Trial: NCT04988386
Drug: Acoramidis (AG10)
RxNorm normalized name: Acoramidis
DrugBank: Acoramidis (DB17999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acoramidis (AG10) twice daily
Trial: NCT05766384
Drug: Hyperpolarized Xe129
RxNorm normalized name: xenon-129, hyperpolarized
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled hyperpolarized 129Xe used as a signal agent for MRI of the lungs.
Trial: NCT04882072
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive IV infusion and SC injection of ustekinumab.
Trial: NCT05338775
Drug: Talquetamab
RxNorm normalized name: Talquetamab
DrugBank: Talquetamab (DB16678)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talquetamab will be administered as a subcutaneous (SC) injection.
Trial: NCT05338775
Drug: Teclistamab
RxNorm normalized name: Teclistamab
DrugBank: Teclistamab (DB16655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teclistamab will be administered as a SC injection.
Trial: NCT05338775
Drug: PD-1 Inhibitor
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The PD-1 inhibitor will be administered as an intravenous injection.
Trial: NCT05632809
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by IV (vein)
Trial: NCT06531811
Drug: AZD8630 (test formulation) via test inhaler
RxNorm normalized name: tuberculin skin test; unspecified formulation
DrugBank: AZD8630 (DB19397)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive AZD8630 via test inhaler.
Trial: NCT06531811
Drug: AZD8630 (reference formulation) via Monodose inhaler
RxNorm normalized name: AZD8630
DrugBank: AZD8630 (DB19397)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive AZD8630 via Monodose inhaler.
Trial: NCT04750577
Drug: BI 685509
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: film-coated tablet
Trial: NCT05957302
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg of ketamine diluted in 10 mL saline (10 mg /mL) and patient will receive 0.1 mL/kg
Trial: NCT06340360
Drug: Rezpegaldesleukin
RxNorm normalized name: Rezpegaldesleukin
DrugBank: Rezpegaldesleukin (DB18992)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Injection solution Route of administration: subcutaneous
Trial: NCT06065462
Drug: Dostarlimab
RxNorm normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given by vein (IV)
Trial: NCT06065462
Drug: LB-100
RxNorm normalized name: LB-100
DrugBank: LB-100 (DB15412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIven by vein (IV)
Trial: NCT06140576
Drug: Sindilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sindilimab, 200mg, Intravenous，every three weeks
Trial: NCT06140576
Drug: Nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel，125mg/m\^2, d1,8, every three weeks
Trial: NCT06140576
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib 8mg, 12mg, 16mg everyday
Trial: NCT05388669
Drug: Lazertinib
RxNorm normalized name: Lazertinib
DrugBank: Lazertinib (DB16216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lazertinib tablets will be administered orally.
Trial: NCT05388669
Drug: Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)
DrugBank: Hyaluronidase (ovine) (DB00070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amivantamab injection will be administered subcutaneously by manual injection.
Trial: NCT05388669
Drug: Amivantamab Intravenous
RxNorm normalized name: amivantamab
DrugBank: Amivantamab (DB16695)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Amivantamab will be administered by IV infusion.
Trial: NCT05213624
Drug: BI 764198
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 764198
Trial: NCT04963725
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: No intervention or treatment will be administered as part of this study. Data available per routine clinical practice at clinic visits as well as directly from participant using a smartphone/tablet application will be collected.
Trial: NCT06179888
Drug: Iberdomide
RxNorm normalized name: Iberdomide
DrugBank: Iberdomide (DB12101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06647498
Drug: Remternetug
RxNorm normalized name: Remternetug
DrugBank: Remternetug (DB18994)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously every 12 weeks
Trial: NCT06531824
Drug: BI 690517
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 690517
Trial: NCT06531824
Drug: Empagliflozin
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin
Trial: NCT05767034
Drug: Secukinumab 300 mg
RxNorm normalized name: secukinumab 300 MG in 2 ML Auto-Injector
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taken subcutaneously every 4 weeks until Week 48 in combination with a 24-week prednisone taper regimen
Trial: NCT05767034
Drug: Secukinumab 150 mg
RxNorm normalized name: secukinumab 150 MG/ML
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taken subcutaneously every 4 weeks until Week 48 in combination with a 24-week prednisone taper regimen
Trial: NCT05834348
Drug: lorlatinib
RxNorm normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: As provided in real world practice
Trial: NCT05834348
Drug: crizotinib
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: As provided in real world practice
Trial: NCT05834348
Drug: brigatinib
RxNorm normalized name: Brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: As provided in real world practice
Trial: NCT05834348
Drug: ceritinib
RxNorm normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: As provided in real world practice
Trial: NCT05834348
Drug: alectinib
RxNorm normalized name: Alectinib
DrugBank: Alectinib (DB11363)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: As provided in real world practice
Trial: NCT05834348
Drug: atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: As provided in real world practice
Trial: NCT05834348
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: As provided in real world practice
Trial: NCT05834348
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: As provided in real world practice
Trial: NCT05834348
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: As provided in real world practice
Trial: NCT05834348
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As provided in real world practice
Trial: NCT05834348
Drug: erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As provided in real world practice
Trial: NCT05834348
Drug: gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As provided in real world practice
Trial: NCT05834348
Drug: afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: As provided in real world practice
Trial: NCT05834348
Drug: dacomitinib
RxNorm normalized name: DACOMITINIB
DrugBank: Dacomitinib (DB11963)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: As provided in real world practice
Trial: NCT05834348
Drug: osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: As provided in real world practice
Trial: NCT05834348
Drug: pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: As provided in real world practice
Trial: NCT05834348
Drug: nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: As provided in real world practice
Trial: NCT05834348
Drug: entrectinib
RxNorm normalized name: ENTRECTINIB
DrugBank: Entrectinib (DB11986)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: As provided in real world practice
Trial: NCT05364554
Drug: JNJ-77242113
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-77242113 tablet will be administered orally.
Trial: NCT05742438
Drug: Lidocaine IV
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of lidocaine
Trial: NCT05742438
Drug: Dexmedetomidine IV
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Continuous intravenous infusion of dexmedetomidine
Trial: NCT05742438
Drug: intrathecal morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intrathecal morphine injection
Trial: NCT06309485
Drug: Sorafenib 400 mg PO, BID continuously
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma.
Trial: NCT06309485
Drug: Sorafenib 400 mg PO, BID
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib is an oral multi-kinase inhibitor used for the treatment of hepatocellular carcinoma.
Trial: NCT05804227
Drug: Ulixertinib
RxNorm normalized name: Ulixertinib
DrugBank: Ulixertinib (DB13930)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take ulixertinib by mouth 2 times every day until the night before your surgery.
Trial: NCT05717062
Drug: Varespladib intravenous form
RxNorm normalized name: Varespladib
DrugBank: Varespladib (DB11909)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a lyophilized drug contained in 100 mg vials to be reconstituted in Water for Injection (WFI), followed by dilution into 0.9% Sodium Chloride Injection.
Trial: NCT05717062
Drug: varespladib-methyl- oral form
RxNorm normalized name: methylal
DrugBank: Varespladib (DB11909)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varespladib-methyl (LY333013) is an immediate-release, oval, white, film-coated tablet at a dosage strength of 250 mg for oral administration.
Trial: NCT06559137
Drug: Ropivacaine 0.2% Injectable Solution
RxNorm normalized name: ROPivacaine 0.2% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients who are randomized to the peripheral nerve block group will receive a pre-operative perineural injection of 0.2% plain Ropivacaine regardless of weight.
Trial: NCT06559215
Drug: Exparel
RxNorm normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to receive Exparel intraoperatively via local infiltration. The dosage will be dependent on patient weight.
Trial: NCT04882033
Drug: Concurrent chemoradiotherapy plus anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anlotinib: for cycle 1-6. P.O; QD; from days 1 to 14 in a 21-day cycle. 8mg in low-dose groups (3 subjects). 10mg in middle-dose groups (3 subjects). 12mg in high-dose groups (3 subjects).~Chemotherapy:~For cycle 1/4/5/6. Etoposide 100mg/m2, d1-3, q3w; Cisplatin 25mg/m2 d1-3, q3w. For cycle 2/3. Etoposide 50mg/m2, d1-3, q4w; Cisplatin 25mg/m2 d1-3, q4w.~Radiotherapy:~For cycle 2/3.Thoracic radiotherapy dose will be 2.0Gy per day, given 5 days a week, to cumulative dose of 60～66Gy.
Trial: NCT05367271
Drug: Botulinum Toxin A
RxNorm normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: 20 units of Onabotulinum A in 200 µL of saline injected into the flexor digitorum brevis via ultrasound-guidance
Trial: NCT05367271
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 mL of 4 mg/mL dexamethasone with 2 mL of 1% lidocaine OR 1 mL of 4 mg/mL dexamethasone, 1 mL of 2% lidocaine and 1 mL saline injected into the plantar fascia
Trial: NCT05197062
Drug: 14C-aticaprant
RxNorm normalized name: urea [14C]
DrugBank: Aticaprant (DB12341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14C-aticaprant will be administered orally as capsule on Day 1.
Trial: NCT06450873
Drug: Coriolus Versicolor Extract
RxNorm normalized name: Iris versicolor root extract
DrugBank: Trametes versicolor fruiting body (DB14287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary Supplement Given PO
Trial: NCT05288777
Drug: T-DM1
RxNorm normalized name: T-DM1
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dosed at 3.6 mg/kg of body weight every 3 weeks for Her2/neu+ patients for a total duration of 14 cycles.
Trial: NCT06171282
Drug: Recombinant oncolytic herpes simplex virus type Ⅰ (R130)
RxNorm normalized name: Dna (recombinant herpes simplex virus type 1 strain kos plasmid vector kb103 human collagen col7a1-specifying)
DrugBank: Tipapkinogene sovacivec (DB06239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11
Trial: NCT05182970
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Individualised target dose of 2000 mg daily depending on tolerability.
Trial: NCT06481891
Drug: Sotagliflozin
RxNorm normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Sotagliflozin will be administered as a tablet(s), orally once daily.
Trial: NCT05407818
Drug: JNJ-63733657
RxNorm normalized name: Immunoglobulin G1, anti-(human phosphorylated tau protein) (human-Mus musculus monoclonal JNJ-63733657 γ1-chain), disulfide with human-Mus musculus monoclonal JNJ-63733657 κ-chain, dimer
DrugBank: Posdinemab (DB18941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-63733657 will be administered as an IV infusion.
Trial: NCT06502964
Drug: ALTO-101
RxNorm normalized name: Altoprev
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ALTO-101 patches
Trial: NCT05307692
Drug: Seltorexant
RxNorm normalized name: Seltorexant
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seltorexant 20 mg will be administered orally as a tablet.
Trial: NCT05421858
Drug: Fosmanogepix
RxNorm normalized name: Fosmanogepix
DrugBank: Fosmanogepix (DB15183)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT05421858
Drug: Fosmanogepix
RxNorm normalized name: Fosmanogepix
DrugBank: Fosmanogepix (DB15183)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT05421858
Drug: Caspofungin
RxNorm normalized name: Caspofungin
DrugBank: Caspofungin (DB00520)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT05421858
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole oral capsule
Trial: NCT06292780
Drug: Linvoseltamab
RxNorm normalized name: Linvoseltamab
DrugBank: Linvoseltamab (DB17447)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-B-cell maturation antigen x anti-Cluster of differentiation 3 bispecific antibody
Trial: NCT05677490
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05677490
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05701189
Drug: Efgartigimod Alfa-Fcab
RxNorm normalized name: efgartigimod alfa-fcab
DrugBank: Efgartigimod alfa (DB15270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Efgartigimod is an anti-neonatal Fc receptor (FcRn) immunoglobulin G1 Fc fragment. The FcRn plans a critical role in extending the half-life of IgGs by rescuing them from lysosomal degradation. Antibodies that bind and subsequently block the FcRn with high affinity result in IgGs being degraded more rapidly instead of salvaged. This approach has been shown to be beneficial in the antibody-mediated disorder myasthenia gravis.
Trial: NCT05701189
Drug: Intravenous Immunoglobulin (IVIg)
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIg is the standard-of-care treatment for GBS. Brand of IVIG used may vary per institutional standards
Trial: NCT05471843
Drug: BGB-11417
RxNorm normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT05483491
Drug: Aldesleukin
RxNorm normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aldesleukin 720,000 IU/kg IV every 8 hours will be preferentially administered as an inpatient within 24 hours after KK-LC-1 TCR-T cell infusion for up to 6 doses; however up to 24 hours may elapse between doses. Aldesleukin dosing will be stopped for aldesleukin-related grade 3 or greater toxicity other than flushing, fever, chills, or hemodynamic changes (tachycardia or hypotension) that respond to crystalloid infusion. Aldesleukin may also be stopped at any time at investigator discretion.
Trial: NCT04811560
Drug: Bleximenib
RxNorm normalized name: Bleximenib
DrugBank: Bleximenib (DB19328)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleximenib is administered orally.
Trial: NCT06389292
Drug: Lisaftoclax (APG-2575)
RxNorm normalized name: APGA
DrugBank: Lisaftoclax (DB18054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, oral administration, every 28 days for a dosing cycle.
Trial: NCT06389292
Drug: Azacitidine Injection
RxNorm normalized name: azacitidine Injection
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: QD, hypodermic or intravenous injection, D1-7 in 28-day cycle.
Trial: NCT05162196
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab 240mg, ivgtt, d1, q3w.
Trial: NCT05162196
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200mg qd
Trial: NCT04929210
Drug: Guselkumab
RxNorm normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Guselkumab will be administered as subcutaneous injection.
Trial: NCT05092269
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ustekinumab will be administered as a SC injection.
Trial: NCT00522470
Drug: rosiglitazone
RxNorm normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06545110
Drug: Baricitinib Oral Tablet
RxNorm normalized name: baricitinib Oral Tablet
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Baricitinib 2/4mg giving to patients with sever alopecia areata after assessment Retinol Binding Protein 4 and its genetic variations.
Trial: NCT05544929
Drug: pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-PD-1 antibody
Trial: NCT05169567
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered orally.
Trial: NCT05169567
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered IM.
Trial: NCT05674487
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction of labor by cervical ripening with Prostaglandins (Misoprostol per os)
Trial: NCT06574100
Drug: Cannabidiol
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients in the first arm cross-over will receive either a single bolus dose of 250mg buccally administered or 1000mg CBD powder and cross over to vice-versa after 21 days.
Trial: NCT06574100
Drug: Cannabidiol
RxNorm normalized name: CANNABIDIOL
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will be randomised to receive 3000mg oral CBD fasting or Fed, they will the cross over to the other group 21 days following the first administration.
Trial: NCT04838964
Drug: MRG003
DrugBank: MRG-003 (DB17407)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrated intravenously